Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
$10.65
-1.3%
$8.74
$5.51
$11.73
$208.95MN/A47,790 shs16,568 shs
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$1.60
-0.1%
$1.46
$1.03
$8.64
$50.07M-0.24498,649 shs31,583 shs
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
$7.25
-1.6%
$54.69
$43.75
$884.98
$210.14M0.9518,713 shs504,908 shs
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
$27.40
+0.2%
$31.91
$0.93
$79.02
$193.01M-5.32821,608 shs3,371 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
+4.66%-1.73%+19.23%+55.70%+1,078,999,900.00%
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-3.03%-6.43%+23.08%+45.45%-83.67%
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
+4.84%-4.47%-92.14%-91.30%-98.69%
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-0.33%-10.12%-15.01%-19.30%+2,066.51%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
1.3938 of 5 stars
3.40.00.00.01.60.00.6
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
0.9717 of 5 stars
3.00.00.00.00.61.70.6
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
3.1019 of 5 stars
3.65.00.00.02.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
3.00
Buy$20.5092.49% Upside
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
2.75
Moderate Buy$4.00150.31% Upside
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
2.00
Hold$78.75986.21% Upside
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
3.25
Buy$83.25203.83% Upside

Current Analyst Ratings Breakdown

Latest ATNM, DRUG, AVTE, and ACTU Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/21/2025
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
5/13/2025
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
5/13/2025
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/13/2025
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
5/12/2025
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
5/7/2025
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$80.00
4/28/2025
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
4/22/2025
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00
4/1/2025
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
3/25/2025
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
3/18/2025
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
N/AN/AN/AN/AN/AN/A
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$81K615.45N/AN/A$1.31 per share1.22
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/AN/AN/AN/A$3.96 per shareN/A
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/AN/AN/AN/A$5.86 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
-$24.75MN/A0.00N/AN/AN/AN/AN/A
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-$48.82M-$1.39N/AN/AN/AN/A-100.85%-47.89%N/A
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%8/11/2025 (Estimated)
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-$2.06M-$0.36N/AN/AN/AN/A-5.85%-5.68%8/13/2025 (Estimated)

Latest ATNM, DRUG, AVTE, and ACTU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
-$0.26-$0.32-$0.06-$0.32N/AN/A
5/15/2025Q2 2025
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-$0.39-$0.29+$0.10-$0.29N/AN/A
4/25/2025Q4 2024
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
-$10.50-$3.15+$7.35-$0.09N/AN/A
3/27/2025Q4 2024
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
-$6.65-$6.65N/A-$0.19N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
N/AN/AN/AN/AN/A
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/AN/AN/AN/AN/A
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/AN/AN/AN/AN/A
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/AN/AN/AN/AN/A

Latest ATNM, DRUG, AVTE, and ACTU Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/9/2025
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
$84.004/29/20254/25/20254/28/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
N/A
1.68
1.68
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/A
10.25
10.25
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/A
8.78
8.78
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/A
126.01
11.31
CompanyEmployeesShares OutstandingFree FloatOptionable
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
1019.62 millionN/AN/A
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
3031.20 million29.32 millionOptionable
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
2028.99 million21.69 millionOptionable
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/A7.04 million4.04 millionNot Optionable

Recent News About These Companies

HC Wainwright Has Bearish Forecast for DRUG Q3 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Actuate Therapeutics stock logo

Actuate Therapeutics NASDAQ:ACTU

$10.65 -0.14 (-1.30%)
As of 11:56 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Actinium Pharmaceuticals stock logo

Actinium Pharmaceuticals NYSE:ATNM

$1.60 0.00 (-0.13%)
As of 11:59 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Aerovate Therapeutics stock logo

Aerovate Therapeutics NASDAQ:AVTE

$7.25 -0.12 (-1.63%)
As of 05/28/2025

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Bright Minds Biosciences stock logo

Bright Minds Biosciences NASDAQ:DRUG

$27.40 +0.05 (+0.18%)
As of 11:58 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.